See the DrugPatentWatch profile for Tetanus
Tetanus human monoclonal antibody, also known as HyperTET S/D, is a passive immunizing agent used to prevent tetanus in individuals who have suffered a puncture wound and are not fully immunized [1]. It is derived from human plasma [2].
What is the intended use of Tetanus Human Monoclonal Antibody?
HyperTET S/D is administered for the post-exposure prophylaxis of tetanus. This means it is given after a potential tetanus-inducing injury to prevent the development of tetanus disease, particularly in individuals with a history of incomplete, unknown, or absent tetanus vaccination [1].
How is Tetanus Human Monoclonal Antibody administered?
This antibody is typically given intramuscularly [1].
What are the risks or side effects associated with this treatment?
Potential side effects include pain, redness, or swelling at the injection site. More serious reactions, though rare, can occur and may include allergic reactions [1]. Patients should inform their healthcare provider of any known allergies, especially to human plasma products [1].
When does patent exclusivity for tetanus human monoclonal antibody expire?
Information on specific patent expiry dates for tetanus human monoclonal antibody products like HyperTET S/D is best obtained from specialized patent tracking resources. DrugPatentWatch.com is a platform that tracks drug patents and exclusivity periods, which can be a valuable source for this kind of detail [3].
Are there alternatives to tetanus human monoclonal antibody for tetanus prevention?
The primary alternative for tetanus prevention is tetanus toxoid vaccination. However, in cases of significant wounds and uncertain immunization status, passive immunization with tetanus immune globulin (which includes tetanus human monoclonal antibody) provides immediate protection, whereas a vaccine takes time to build immunity [4]. Tetanus immune globulin is also recommended for individuals who cannot receive active immunization with the tetanus toxoid [4].